Located in New Haven, Connecticut, Yale Cancer Center is a collaborative effort between two highly respected organizations: the Yale School of Medicine, a well-known medical school and Smilow Cancer Hospital at Yale-New Haven.
It’s impossible to think about cancer treatment today without touching on a treatment that was pioneered at Yale University, namely, chemotherapy. Cancer chemotherapy and cancer drug development was discovered at Yale, and the first-ever cancer drug was administered there in 1942. The university has also played a role in other cancer milestones. As far back as the early 1900s, a Yale doctor developed a method for growing tumor cells, an important step in understanding how tumors develop. Later, the first FDA-approved selective immunotherapy treatment for cancer was developed at the university.
Over the past four decades, the center has grown into a powerhouse for research, technology and clinical care.Its successes are rooted in research. By emphasizing the molecular origins of cancer, the Yale Cancer Center promotes treatments that are created for specific types of cancers. Through this process, which the center calls “personalized medicine,” the patient can expect more targeted treatments and fewer side effects. In recent years, Yale Cancer Center has seen its facilities brought up to par with its reputation. In 2009, Yale-New Haven Hospital opened a 14-story, state-of-the-art facility specifically designed for the delivery of cancer treatment.
In terms of the treatment of mesothelioma, Yale understands and supports the common treatments of surgery, radiation therapy and chemotherapy. They strive to use a multidisciplinary approach with a team of medical oncologists, radiation oncologists and surgeons. They also support the use of clinical trials if it’s in the best interest of the patient and their particular case.
- Multimodal treatment
- Clinical trials
- Mesothelioma and other asbestos-related conditions
- Connecticut Magazine Best Doctors recognition
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Last Updated: November 1, 2019
Conditions: Carcinoma, Carcinoma, Squamous Cell, Adenocarcinoma, Neoplasms, Germ Cell and Embryonal, Mesothelioma, Breast Neoplasms, Cholangiocarcinoma, Nasopharyngeal Carcinoma, Carcinoma, Basal Cell, Gastrointestinal Stromal Tumors, Carcinoid Tumor, Carcinoma, Transitional Cell, Carcinoma, Adenoid Cystic, Teratoma, Adenocarcinoma of Lung, Carcinoma, Neuroendocrine, Pheochromocytoma, Seminoma, Choriocarcinoma, Cystadenocarcinoma, Cystadenocarcinoma, Serous, Carcinoma, Endometrioid, Paraganglioma, Chordoma, Fibromatosis, Aggressive, Hemangiosarcoma, Trophoblastic Neoplasms, Adenocarcinoma, Mucinous, Gestational Trophoblastic Disease, Adenocarcinoma, Clear Cell, Nerve Sheath Neoplasms, Neurofibrosarcoma, Fibroma, Thyroid Neoplasms, Cystadenocarcinoma, Mucinous, Pseudomyxoma Peritonei, Vulvar Neoplasms, Sex Cord-Gonadal Stromal Tumors, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Paget Disease, Extramammary, Adenocarcinoma, Papillary, Carcinoma, Acinar Cell, Adenocarcinoma, Bronchiolo-Alveolar, Mixed Tumor, Mullerian, Carcinoma, Giant Cell, Neoplasms, Unknown Primary, Neoplasms
Last Updated: April 28, 2020
- Mesothelioma Doctors
- Cancer Centers
- Treatment Near You
- Experimental Treatments
- Alternative Treatments
- Clinical Trials
- Caregiver Resources
- Treatment Costs